Skip To Main Content
Mehlam Saifudeen on Muck Rack

Mehlam Saifudeen

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Mehlam

Contact Mehlam, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Comprehensive profiling of clinically approved kinase inhibitors reveals mutation-specific inhibitors and opportunities for drug repurposing

|
By Songli Zhu, Haiching Ma, Marina Chan, Taranjit S Gujral, Mehlam Saifudeen, Shuguang Liang, Mia Eason, Alison Goupil, Deanna F. Mische, Christian M. Loch
| Nature Verified
Abstract Protein kinases are central to cell signaling and key drug targets in cancer. To inform potential repurposing of kinase inhibitors, we profiled 86 of the ~100 approved kinase inhibitors against 758 kinases, including 409 wild-type and 349 oncogenic variants using a biochemical kinase assay. Our results increase the number of druggable kinases from 89 to 235, revealing that 94% of mutations and 97% of fusions represented in our samples are inhibited by at least one existing drug.
Open in Who Shared Issue with article?
See all 1 articles